{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-057737","form_type":"8-K","ticker":"BRKR","cik":"0001109354","company_name":"BRUKER CORP","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.249965+00:00","generated_at":"2026-06-08T23:21:48.216914+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bruker Q3: Rev $742.8M, Non-GAAP EPS $0.74, FY organic guidance raised to 11.5-12.5%","bullets":["Q3 revenue $742.8M (+16.3% YoY); organic +10.9%, acquisitions +2.1%, FX +3.3%.","Q3 GAAP EPS $0.60; Non-GAAP EPS $0.74 (+12.1% YoY).","BSI segment revenue $676.3M (+16.1% YoY); BEST segment $70.6M (+19.1%).","FY 2023 revenue guidance raised to $2.88-$2.91B; organic growth 11.5-12.5% (+150 bps midpoint).","Cellular Analysis (PhenomeX) acquired Oct 2; slightly dilutive in FY24, accretive by FY26."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-057737","json":"https://secwatch.observer/filing/0000950170-23-057737.json","markdown":"https://secwatch.observer/filing/0000950170-23-057737.md","text":"https://secwatch.observer/filing/0000950170-23-057737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1109354/000095017023057737/0000950170-23-057737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1109354/000095017023057737/brkr-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:21:48.216914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e8b4e30e6f63feb92c5e5e4cbf26d9d0c579ebde","claim":"BRUKER CORP reported the third quarter ended September 30, 2023 results: revenue $742.8 million, EPS $0.60 GAAP diluted EPS; $0.74 non-GAAP diluted EPS. Guidance raised.","evidence_excerpt":"Bruker Reports Third Quarter 2023 Financial Results • Q3 2023 revenues of $742.8 million, up 16.3% year-over-year (yoy); organic revenue up 10.9% yoy • Q3 2023 GAAP EPS $0.60; non-GAAP EPS $0.74, up 12.1% yoy • Bruker increases FY 2023 revenue guidance to $2.88-$2.91 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1109354/000095017023057737/0000950170-23-057737-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$742.8 million"},{"label":"EPS","value":"$0.60 GAAP diluted EPS; $0.74 non-GAAP diluted EPS"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fafb7d27fcbb5f9d72604f9a193097d933c37521","claim":"BRUKER CORP reported the first nine months ended September 30, 2023 results: revenue $2.11 billion, EPS $1.50 GAAP diluted EPS; $1.88 non-GAAP diluted EPS. Guidance raised.","evidence_excerpt":"First Nine Months of 2023 Financial Results For the first nine months of 2023, Bruker’s revenues were $2.11 billion, an increase of 15.8% from $1.82 billion in the first nine months of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1109354/000095017023057737/0000950170-23-057737-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first nine months ended September 30, 2023"},{"label":"Revenue","value":"$2.11 billion"},{"label":"EPS","value":"$1.50 GAAP diluted EPS; $1.88 non-GAAP diluted EPS"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}